In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Development of a qualitative and quantitative detection method for the N-terminal fragment of cardiac myosin-binding protein C

Session Poster Session 5

Speaker Athiththan Yogeswaran

Event : ESC Congress 2018

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Biomarkers
  • Session type : Poster Session

Authors : A Yogeswaran (Giessen,DE), C Lipps (Giessen,DE), T Keller (Bad Nauheim,DE), C Liebetrau (Bad Nauheim,DE), O Doerr (Giessen,DE), S Wolter (Bad Nauheim,DE), S Voss (Bad Nauheim,DE), S Kriechbaum (Bad Nauheim,DE), M Aslam (Giessen,DE), S Sadayappan (Cincinnati,US), C W Hamm (Giessen,DE), C Troidl (Bad Nauheim,DE)

A. Yogeswaran1 , C. Lipps1 , T. Keller2 , C. Liebetrau2 , O. Doerr3 , S. Wolter2 , S. Voss2 , S. Kriechbaum2 , M. Aslam1 , S. Sadayappan4 , C.W. Hamm3 , C. Troidl2 , 1Justus-Liebig University of Giessen, Experimental Cardiology - Giessen - Germany , 2Kerckhoff Heart and Thorax Center, Department of Cardiology - Bad Nauheim - Germany , 3University Hospital Giessen and Marburg, Department of Angiology and Cardiology - Giessen - Germany , 4University of Cincinnati, Internal Medicine - Cincinnati - United States of America ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 996-997

Background: Cardiac myosin-binding protein C (MYBPC3) was recently discovered as a new biomarker for acute coronary syndrome. Due to the active and early cleavage of MYBPC3, the N-terminal fragment C0-C1f is released within the first minutes of ischemia and during the early reperfusion phase. Even though C0-C1f has been proposed to be a novel early cardiac biomarker, there is no known specific detection method for this peptide.

Purpose: Our aim is to establish a detection method for qualitative and quantitative detection of C0-C1f. The core benefit of this assay will be the evaluation of C0-C1f as a novel cardiac biomarker for non-invasive differential diagnosis of non-ST-elevation myocardial infarction.

Methods: An indirect sandwich enzyme-linked immunosorbent assay (ELISA) was developed for the detection of C0-C1f and the full-length protein MYBPC3. Using a monoclonal mouse antibody against the N-terminus of MYBPC3 developed for this assay, the parameters of the ELISA were optimized to obtain a sensitive detection method. Its specificity was confirmed by western blotting. Prefixed depletion using a magnetic bead-conjugated antibody against the intermediary region of MYBPC3 was applied to remove analogue epitopes that differ from the target C0-C1f (e.g. C0-C2 and full-length). The efficiency of this method was confirmed via mass spectrometry and ELISA.

Results: Cross-reactivity of the antibodies used regarding slow and fast skeletal myosin-binding protein C and mouse isoforms was determined and specificity for the cardiac isoform was verified. The ELISA is precise and sensitive with a lower limit of detection of 0.05 ng/mL and its characteristics, such as dilution-linearity and recovery values correspond to the accepted standards. MYBPC3 plasma levels of healthy individuals (n=4) are 10 ng/mL respectively.

Conclusions: This assay is the first method developed for measuring the concentration of C0-C1f. It is suitable for qualitative and quantitative detection of C0-C1f. This method may aid in evaluating the role of C0-C1f in progression and development of cardiac diseases. As a next step, the concentration of C0-C1f in different cardiac diseases, including acute coronary syndrome, and its release kinetics will be determined to evaluate its utility as a novel cardiac biomarker

Assay characteristics
TypeSandwich ELISA
Detection methodFluorescent
ReactivityHuman, Mouse
SpecifityCardiac Myosin-binding Protein C; No significant cross-reactivity or interference between MYBPC3 and analogs was observed
Lower Limit of Detection50 ng/L

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are